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Abstract: Consumption of soybean products has been implicated in the prevention of breast cancer.
This study provides insights into the anti-proliferative activity of 12 anticarcinogens from soybean by
single or two-way combination treatment against MCF-7 and MDA-MB-231 human breast cancer
cells. Results showed that genistein, daidzein, glycitein, genistin and dainzin showed stronger
anti-proliferative activity against MCF-7 cells with EC50 values of 66.98 ± 4.87 µM, 130.14 ± 2.10 µM,
190.67 ± 5.65 µM, 72.82 ± 2.66 µM and 179.21 ± 6.37 µM, respectively. There is a synergistic effect of
combination treatment of genistin plus daidzin in MCF-7 cells with combination index at inhibition
of 50% (CI50) of 0.89 ± 0.12. Genistein, glycitein, genistin and β-sitosterol were demonstrated to have
a stronger anti-proliferative activity against MDA-MB-231 cells with EC50 values of 93.75 ± 5.15 µM,
142.67 ± 5.88 µM, 127.82 ± 4.70 µM and 196.28 ± 4.45 µM. The synergistic effect was observed in the
mixture of genistein plus genistin, genistein plus β-sitosterol or β-sitosterol plus genistin with CI50
values of 0.56 ± 0.13, 0.54 ± 0.20 and 0.45 ± 0.12, respectively. These bioactive anticarcinogens were
able to inhibit invasion and migration of breast cancer cells and the combination treatments enhanced
the inhibitory effect. Regulation of PI3K/Akt/mTORpathway seems to be the main mechanisms
involved in the anticancer activity.
Keywords: soybean; synergistic effect; MDA-MB-231; MCF-7; anti-proliferation
1. Introduction
Epidemiological evidence suggests that an increased consumption of soybean food is associated
with a decreased cancer risk [1]. Soybean food has been recommended in cancer prevention for a
number of anticarcinogens exist in it. Soybean isoflavones, a family of nonnutritive compounds,
were demonstrated to be associated with modulation of a variety of biological processes in
carcinogenesis [2]. Equol, derived from isoflavones by the action of gut microflora, was reported to
inhibit cancer cell growth and invasion with higher bioavailability [3]. Phytosterols are plant sterols
chemically similar to cholesterol but exclusively in plants, particularly legumes. Awad et al. [4]
found that it could induce apoptosis in breast cancer cells. In addition, a previous study indicated
that soybean saponins could suppress the growth of colon tumor cells in vitro [5]. Except these
phytochemicals, soybean also provides a source of bioactive proteins and polypeptides which are now
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being intensively studied as cancer chemopreventive agents, such as trypsin inhibitor, lectin and a
recently discovered peptide lunasin [6–8].
Breast cancer is the most frequently diagnosed cancer and one of the major causes of mortality
in woman [9]. The conventional treatment methods of breast cancer would bring irreversible side
effects to patients. Although a lot of work on prevention and intensive treatment of breast cancer
has been done, effective strategies with minor side effects are still lacking [10]. Breast cancer is a
heterogeneous disease, classified into different subtypes according to the gene expression profile or
immunohisto chemical markers such as estrogen receptor (ER) [11]. MCF-7 and MDA-MB-231 human
cancer cell lines are ER+ and ER− cells, which are well-established in vitro model for evaluation of
estrogen responsive or estrogen independent antineoplastic drugs [12]. Recently, increasing evidences
suggested that the abundant anticarcinogens in soybean have obvious ability to prevent and treat
breast cancer. However, it now remains to identify the most bioactive anticarcinogens from soybean
on different subtypes of breast cancer cells.
The low concentration and low bioavailability of active components in natural plants limited their
clinical application [13]. It is reported that chemotherapeutic combination approaches could reach a
greater effect than with one active compounds single at equal concentrations [10], which is called a
synergistic effect. Synergistic anticancer effect has been observed with different compounds or bioactive
components derived from natural plants such as arctigenin and quercetin [14], and phytochemicals
enriched apple extracts and quercetin 3-β-D-glucoside [10]. However, limited knowledge is available
regarding the synergistic effect of anticarcinogens in soybean on inhibition of proliferation of breast
cancer cells.
In this study, the anti-proliferative activity of 12 reported anticarcinogens individually from
soybean in MDA-MB-231 and MCF-7 human breast cancer cells was firstly evaluated by single
treatment. Then, anticarcinogens showing stronger activity were taken forward to investigate whether
there is a synergistic effect on human breast cancer cell proliferation by two-way combination treatment.
2. Results and Discussion
2.1. Anti-Proliferative Effects of 12 Treatment Solutions on Human Breast Cancer Cells by Single Treatment
and Combination Treatment
To realize the aims of this study, 12 reported anticarcinogens from soybean were collected and
screened for their anti-proliferative activity against the MCF-7 and MDA-MB-231 human breast cancer
cells. As shown in Figure 1a,b, within the concentrations determined (0–200 µM), BBI and lunasin
have no significant anti-proliferative effect on MCF-7 cells. Genistein, daidzein, glycitein, genistin,
daidzin, glycitin, equol, soyasaponin, β-sitosteroland lectin inhibited the MCF-7 cell proliferation in
a dose-dependent manner. Among these 10 bioactive anticarcinogens, genistein, daidzein, glycitein,
genistin and daidzin were demonstrated to have stronger anti-proliferative activity, with the EC50
values (Figure 2a) of 66.98 ± 4.87 µM, 130.14 ± 2.10 µM, 190.67 ± 5.65 µM, 72.82 ± 2.66 µM and
179.21 ± 6.37 µM, respectively. MCF-7 human breast cancer cells are estrogen-responsive breast
cancer cells. The anti-proliferative activity of soybean isoflavones has been previously and widely
demonstrated in estrogen-responsive breast cancer cells in vitro [15]. Recently, considerable interest
has focused on the triple negative breast cancer which is an aggressive subtype of breast cancer and
more frequent in younger and pre-menopausal women [16]. MDA-MB-231 human breast cancer cells
are the estrogen-independent, triple negative breast cancer cells. Results of the present study showed
that single treatments with daidzin, BBI, equol, lectin and lunasin at concentrations less or equal
than 200 µM showed no significant inhibition effects on MDA-MB-231 cell proliferation. However,
genistein, glycitein, genistin and β-sitosterol exhibited stronger anti-proliferative effects against
MDA-MB-231 cells in a dose-dependent manner, with the EC50 values (Figure 2b) of 93.75 ± 5.15 µM,
142.67 ± 5.88 µM, 127.82 ± 4.70 µM and 196.28 ± 4.45 µM, respectively. These results suggested that
MCF-7 cells were more sensitive to anticarcinogens from soybean than MDA-MB-231 cells.
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Figure 1. Percent inhibition of MCF-7 (a) and MDA-MB-231 (b) human cancer cells proliferation by 
12 anticarcinogens from soybean. Cells were respectively treated with different concentrations (0–
200 μM) of 12 samples. Data are presented as mean ± SD. * indicates a significant difference 
compared to the control in cell proliferation assay at concentration of 200 μM (p < 0.05). 
Due to obvious anti-proliferative activity of compounds from natural plants, the dietary 
modification is thought to be an alternative strategy to prevent and reduce the risk of breast cancer 
[10]. However, the effective doses of these compounds can barely be achieved by oral consumption. 
Nowadays, the synergistic effect generated from drug combination has attracted great attention due 
to the advantage of increased anti-cancer effect, lesser drug dose, reduced side effects. To further 
investigate whether there is a synergistic effect of anticarcinogens from soybean, samples showing 
Figure 1. Percent inhibitio of MCF-7 (a) and MDA-MB-231 (b) human a cer cells proliferation
by 12 anticarcinogens from soybean. Cells were respectively treated with different concentrations
(0–200 µM) of 12 samples. Data are presented as mean ± SD. * indicates a significant difference
compared to the control in cell proliferation assay at concentration of 200 µM (p < 0.05).
Due to obvious anti-proliferative activity of compounds from natural plants, the dietary
modification is thought to be an alternative strategy to prevent and reduce the risk of breast cancer [10].
However, the effective doses of these compounds can barely be achieved by oral consumption.
Nowadays, the synergistic effect generated from drug combination has attracted great attention
due to the advantage of increased anti-cancer effect, lesser drug dose, reduced side effects. To further
investigate whether there is a synergistic effect of anticarcinogens from soybean, samples showing
stronger anti-proliferative activity by single treatment were selected and two-way combination
treatments were conducted respectively in MCF-7 and MDA-MB-231 cells. Ten combination treatments
including genistein plus daidzein, genistein plus glycitein, genistein plus genistin, genistein plus
daidzin, daidzein plus glycitein, daidzein plus genistin, daidzein plus daidzin, glycitein plus genistin,
glycitein plus daidzin and genistin plus daidzin were performed on MCF-7 cells (Figure 2a). The CI
values were calculated for all the ten combination treatment at 50% inhibition of MCF-7 proliferation.
Results (Table 1) showed that only the CI50 value of the combination of genistin plus daidzin was less
than 1 (0.89 ± 0.12), indicating that there was a synergistic effect by the combined treatment of genistin
plus daidzin in MCF-7 cells. The EC50 value of genistin and daidzin were reduced to 26.21 ± 3.72 µM
and 64.50 ± 3.88 µM, respectively, due to the synergistic effect. Six combination treatments including
genistein plus glycitein, genistein plus genistin, genistein plus β-sitosterol, glycitein plus genistin,
glycitein plus β-sitosterol and β-sitosterol plus genistin were conductedtoward MDA-MB-231 cells and
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results are presented in Figure 2b. The CI50 values of two-way combination treatments of genistein plus
genistin, genistein plus β-sitosterol and β-sitosterol plus genistin for MDA-MB-231 cell proliferation
were 0.56 ± 0.13, 0.54 ± 0.20 and 0.45 ± 0.12, respectively (Table 1)These results suggested that there
were significant synergistic effects of these three combination treatments. The EC50 values of genistein,
genistin and β-sitosterol in these two-way combination treatments were significantly lower than in
single treatments. The EC50 values of β-Sitosterol and genistin toward MDA-MB-231 reduced to
37.71 µM and 24.55 µM, less than 50 µM. It is reported that soybean isoflavone concentrations in
prostatic fluid can reach up to 50 µM in persons with a long-term soybean-rich dietary habits [17].
The synergistic effects of these combination treatments increase the possible application of natural
anticarcinogens in humans.
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Figure 2. EC50 values of bioactive anticarcinogens by single or two-way combination treatment in 
MCF-7 (a) and MDA-MB-231 (b) human cancer cells. Data are presented as mean ± SD. * Indicates a 
significant difference compared to the EC50 value of single treatment (p < 0.05). 
Table 1. CI50 values a of bioactive anticarcinogens by single or two-way combination treatment in 
MCF-7 and MDA-MB-231 human cancer cells. 
 Combined Treatments CI Value at Inhibition of 50% 
MCF-7 
Genistein + Daidzein 2.02 ± 0.30 
Genistein + Glycitein 1.86 ± 0.22 
Genistein + Genistin 1.53 ± 0.33 
Genistein + Daidzin 1.52 ± 0.18 
Daidzein + Glycitein 1.68 ± 0.44 
Daidzein + Genistin 1.69 ± 0.31 
Daidzein + Daidzin 1.89 ± 0.23 
Glycitein + Genistin 1.92 ± 0.58 
Glycitein + Daidzin 1.01 ± 0.10 
Genistin + Daidzin 0.89 ± 0.12 
MBA-MD-231 
Genistein + Glycitein 1.30 ± 0.08 
Genistein + Genistin 0.56 ± 0.13 
Genistein + β-Sitosterol 0.54 ± 0.20 
Glycitein + Genistin 1.05 ± 0.10 
Glycitein + β-Sitosterol 1.29 ± 0.07 
β-Sitosterol + Genistin 0.45 ± 0.12 
a The combination index at inhibition of 50%. 
2.2. Cytotocicity of Bioactive Anticarcinogens by Single or Two-Way Combination Treatment 
At the concentration of the EC50 values, the cytotoxicity of genistein, daidzein, glycitein, 
genistin, daidzin and genistin plus daidzin toward MCF-7 cells, and the cytotoxicity of genistein, 
glycitein, genistin, β-sitosterol, genistein plus genistin, genistein plus β-sitosterol and β-sitosterol 
plus genistin toward MDA-MB-231 cells are shown in Figure 3a,b. No cytotoxicity was observed in 
genistein, daidzein, genistin and genistin plus daidzin toward MCF-7 cells. In addition, there was 
Figure 2. EC50 values of bioactive anticarcinogens by single or two-way combination treatment in
MCF-7 (a) and MDA-MB-231 (b) human cancer cells. Data are presented as mean ± SD. * Indicates a
significant difference compared to the EC50 value of single treatment (p < 0.05).
2.2. Cytotocicity of Bioactive Anticarcinogens by Single or Two-Way Combination Treatment
At the concentration of the EC50 values, the cytotoxicity of genistein, daidzein, glycitein, genistin,
daidzin and genistin plus daidzin toward MCF-7 cells, and the cytotoxicity of genistein, glycitein,
genistin, β-sitosterol, genistein plus genistin, geni tein plus β-sitosterol and β-sitosterol plus genistin
toward MDA-MB-231 cells are shown in Figure 3a,b. No cytotoxicity was observed in genistein,
daidzein, genistin and genistin plus daidzi toward MCF-7 cells. In addition, there was no cytotoxicity
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in genistein, genistin, genistein plus genistin, genistein plus β-sitosterol and β-sitosterol plus genistin
toward MDA-MB-231 cells.
Table 1. CI50 values a of bioactive anticarcinogens by single or two-way combination treatment in
MCF-7 and MDA-MB-231 human cancer cells.
Combined Treatments CI Value at Inhibition of 50%
MCF-7
Genistein + Daidzein 2.02 ± 0.30
Genistein + Glycitein 1.86 ± 0.22
Genistein + Genistin 1.53 ± 0.33
Genistein + Daidzin 1.52 ± 0.18
Daidzein + Glycitein 1.68 ± 0.44
Daidzein + Genistin 1.69 ± 0.31
Daidzein + Daidzin 1.89 ± 0.23
Glycitein + Genistin 1.92 ± 0.58
Glycitein + Daidzin 1.01 ± 0.10
Genistin + Daidzin 0.89 ± 0.12
MBA-MD-231
Genistein + Glycitein 1.30 ± 0.08
Genistein + Genistin 0.56 ± 0.13
Genistein + β-Sitosterol 0.54 ± 0.20
Glycitein + Genistin 1.05 ± 0.10
Glycitein + β-Sitosterol 1.29 ± 0.07
β-Sitosterol + Genistin 0.45 ± 0.12
a The combination index at inhibition of 50%.
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Figure 3. Cytotoxicity of bioactive anticarcinogens by alone or two-way combination treatment in 
MCF-7 (a) and MDA-MB-231 (b) human cancer cells. Data are presented as mean ± SD. * Indicates a 
significant difference compared to the control (p < 0.05). 
2.3. Inhibition of Cell Invasion and Migration 
The invasive and migratory ability is the important characteristic of metastasis of tumor cells 
[18]. To further evaluate the pharmacological activity of these anticarcinogens against cancer 
metastasis, wound-healing assay and transwell chamber assay were performed to evaluate the 
inhibition of cell invasion and migration. As shown in Figure 4a,b, treatment of MCF-7 cells with 
genistein, daidzein, glycitein, genistin or daidzin single led to decreased wound closure compared to 
control cells by 49.49%, 46.22%, 47.24%, 34.98% and 38.49%, respectively, suggesting that these 
samples reduced the motility of MCF-7 cells. The mixture of genistin plus daidzin inhibited the 
wound closure by 59.48%, significantly more (p < 0.05) than treatment with genistin or daidzin 
single. Genistein, glycitein, genistin and β-sitosterol were able to inhibit the wound closure in 
MDA-MB-231 (Figure 4c,d). They decreased wound closure compared to control cells by 57.27%, 
24.93%, 5.19% and 15.67%. Genistein plus genistin, Genistein plus β-sitosterol, and β-sitosterol plus 
genistin decreased wound closure by 55.56%, 27.49% and 45.51%. However, among these 
combination treatments, only the mixture of β-sitosterol and genistin showed significantly stronger 
(p < 0.05) inhibitory effect than single treatment in MDA-MB-231 cells. 





Figure 3. Cytotoxicity of bioactive anticarcinogens by alone or two-way combination treatment in
MCF-7 (a) and MDA-MB-231 (b) human cancer cells. Data are presented as mean ± SD. * Indicates a
significant difference compared to the control (p < 0.05).
2.3. Inhibition of Cell Inv sion and Migration
The invasive and migratory ability is the important characteristic of metastasis of tumor cells [18].
To further evaluate the pharmacological activity of these anticarcinogens against cancer metastasis,
wound-h aling assay a d transwell chamber assay w r performed to evaluate the inhibition of cell
invasion a d migration. As shown in Figure 4a,b, treatment of MCF-7 cells with genistein, daidzein,
glycitein, genistin or daidzin single led to decreased wound closure compared to control cells by 49.49%,
46.22%, 47.24%, 34.98% and 38.49%, respectively, suggesting that these samples reduced the motility of
MCF-7 cells. The mixture of genistin plus daidzin inhibited the wound closure by 59.48%, significantly more
(p < 0.05) than treatment with genistin or daidzin single. Ge istein, glycitein, genistin and β-sitosterol
were able to i hibit the wound closure in MDA-MB- 31 (Figure 4c,d). They dec eased wound closure
compared to control cells by 57.27%, 24.93%, 5.19% and 15.67%. Genistein plus genistin, Genistein plus
β-sitosterol, and β-sitosterol plus genistin decreased wound closure by 55.56%, 27.49% and 45.51%.
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However, among these combination treatments, only the mixture of β-sitosterol and genistin showed
significantly stronger (p < 0.05) inhibitory effect than single treatment in MDA-MB-231 cells.
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Figure 4. Inhibition of cell invasion and migration measured by wound healing assay and transwell 
chamber assay. For wound-healing assay, wounds were made when cells were 90–100% confluent. 
Overnight, cells were treated with samples, or control. The closure of wounds in MCF-7 cells and 
MDA-MB-231 cells were imaged (a,c) and quantitatively measured (b,d) at 0 h and 24 h. For 
transwell chamber assay, MCF-7 (e) and MDA-MB-231 (f) Cells were treated with samples, or 
control for 48 h. Cells suspended in serum-free medium were seeded on the upper membrane of 
transwell chamber and incubated for 48 h. Complete growth medium was added on the bottom. 
Cells on the lower membrane of chambers were counted. Data are presented as mean ± SD. * 
indicates a significant difference compared to the control (p < 0.05). # indicates a significant 
difference compared to treatment with samples by single (p < 0.05). 
Results of the transwell assay showed that gensitein, daidzein, glycitein, genistin and daidzin 
have a positive effect on MCF-7 cell migration (Figure 4e). The migration of MCF-7 cells was 
respectively inhibited by 65.43%, 57.04%, 42.04%, 38.19% and 62.03% with gensitein, daidzein, 
glycitein, genistin and daidzin treatment compared to control. The combination treatment of 
genistin plus daidzin significantly enhanced (p < 0.05) the inhibition compared to genistin and 
daidzin alone. The inhibitory effects of genistein, glycitein, genistin and β-sitosterol on 
MDA-MB-231cell migration were also examined (Figure 4f). Similar to results of the wound-healing 
assay, genistein, glycitein, genistin and β-sitosterol led to a significant decrease (p < 0.05) in 
MDA-MB-231 cell migration, however, genistin had no significant effect by single treatment. Three 
combination treatments also showed significant inhibitory effects on MDA-MB-231 cell migration, 
however, only combination of genistin plus β-sitosterol enhanced the effects compared to genistin 
and β-sitosterol alone.  
Overall, all the data indicate that the bioactive anticarcinogens, except genistin, from soybean 
effectively decreased the invasive and migratory ability of MCF-7 cells and MDA-MB-231 cells. The 
combination treatment could enhance the inhibitory effect. The inhibitory effect on the invasion and 
migration of cancer cells is not due to the cytotoxicity. 
2.4. Modulations of Protein Expression and Signaling Pathways 
The anti-proliferative effect and inhibitory effect on cell invasion and migration of 
anticarcinogens was associated with changes in multiple signaling pathways [14]. In order to explore 
the involved signaling pathways of single treatments and combination treatments in MCF-7 and 
MD-MB-231 cells, the protein expression levels of 18 intracellular signaling molecules (Figure 5a) 
were examined. 
In MCF-7 cells (Figure 5b,c), results showed that genistein significantly (p < 0.05) decreased 
phosphorylation of stat3, Akt, and PRAS40; Daidzein significantly (p < 0.05) decreased 
phosphorylation of stat3 and PRAS40; Glycitein significantly (p < 0.05) decreased phosphorylation 
of stat3, and increased phosphorylation of 5′AMP-activated protein kinase (AMPK) α; Daidzin 
Figure 4. Inhibition of cell invasion and migratio m asur d by wound healing assay and transwell
chamber assay. For wound-healing assay, wounds were made when cells were 90–100% confluent.
Overnight, cells were tre ted with samples, or control. Th closure of ounds in MCF-7 cells and
MDA-MB-231 cells were imaged (a,c) and quantitatively measured (b,d) at 0 h and 24 h. For transwell
chamber assay, MCF-7 (e) and MDA-MB-231 (f) C lls were tre ted with sa ples, or control for 48 h.
Cells suspended in serum-free medium were seeded on the upper membrane of transwell chamber
and incubated for 48 h. Complete growth medium was added on the bottom. Cells on the lower
membrane of chambers were counted. Data are presented as mean ± SD. * indicates a significant
difference compared to the control (p < 0.05). # indicates a significant difference compared to treatment
with samples b si gle (p < 0.05).
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Results of the transwell assay showed that gensitein, daidzein, glycitein, genistin and daidzin
have a positive effect on MCF-7 cell migration (Figure 4e). The migration of MCF-7 cells was
respectively inhibited by 65.43%, 57.04%, 42.04%, 38.19% and 62.03% with gensitein, daidzein, glycitein,
genistin and daidzin treatment compared to control. The combination treatment of genistin plus
daidzin significantly enhanced (p < 0.05) the inhibition compared to genistin and daidzin alone.
The inhibitory effects of genistein, glycitein, genistin and β-sitosterol on MDA-MB-231cell migration
were also examined (Figure 4f). Similar to results of the wound-healing assay, genistein, glycitein,
genistin and β-sitosterol led to a significant decrease (p < 0.05) in MDA-MB-231 cell migration, however,
genistin had no significant effect by single treatment. Three combination treatments also showed
significant inhibitory effects on MDA-MB-231 cell migration, however, only combination of genistin
plus β-sitosterol enhanced the effects compared to genistin and β-sitosterol alone.
Overall, all the data indicate that the bioactive anticarcinogens, except genistin, from soybean
effectively decreased the invasive and migratory ability of MCF-7 cells and MDA-MB-231 cells.
The combination treatment could enhance the inhibitory effect. The inhibitory effect on the invasion
and migration of cancer cells is not due to the cytotoxicity.
2.4. Modulations of Protein Expression and Signaling Pathways
The anti-proliferative effect and inhibitory effect on cell invasion and migration of anticarcinogens
was associated with changes in multiple signaling pathways [14]. In order to explore the involved
signaling pathways of single treatments and combination treatments in MCF-7 and MD-MB-231 cells,
the protein expression levels of 18 intracellular signaling molecules (Figure 5a) were examined.
In MCF-7 cells (Figure 5b,c), results showed that genistein significantly (p < 0.05) decreased
phosphorylation of stat3, Akt, and PRAS40; Daidzein significantly (p < 0.05) decreased phosphorylation
of stat3 and PRAS40; Glycitein significantly (p < 0.05) decreased phosphorylation of stat3,
and increased phosphorylation of 5′AMP-activated protein kinase (AMPK) α; Daidzin significantly
(p < 0.05) increased phosphorylation of AMPKα. By combination treatment of genistin plus daidzin,
phosphorylation of stat3, mammalian target of rapamycin (mTOR) and PRAS40 were significantly
(p < 0.05) decreased, and phosphorylation of AMPKα was significantly (p < 0.05) increased.
In MDA-MB-231 cells, genisitein significantly (p < 0.05) downregulated phosphorylation of Akt, mTOR,
p38, PRAS40 and GSK-3β, and upregulated phosphorylation of BAD and p53; Glycitein significantly
(p < 0.05) downregulated phosphorylation of Akt, mTOR, p38, PRAS40 and GSK-3β, and upregulated
phosphorylation of AMPKα; Genistin significantly (p < 0.05) downregulated phosphorylation of Akt,
mTOR and GSK-3β, and upregulated phosphorylation of BAD and p53; β-Sitosterol significantly
downregulated phosphorylation of Akt, BAD, p53, p38 PRAS40 and GSK-3β, and upregulated AMPKα.
Three combination treatments showed similar pattern with significantly (p < 0.05) upregulation
of phosphorylated AMPKα, BAD and p53, but not significantly (p > 0.05) downregulation of
phosphorylated Akt and mTOR. These results suggested that these anticarcinogens exerted anticancer
effect in MCF-7 and MDA-MB-231 cells via different signaling pathways.
From these results, almost all treatments upregulated phosphorylation of AMPKα in varied
degrees. AMPK is a serine/threonine protein kinase which responsible for cellular energy
homeostasis [18]. Published studies indicate that AMPK activation strongly suppresses cell
proliferation in non-malignant cells as well as in tumour cells. These actions of AMPK appear to be
mediated through multiple mechanisms including regulation of the cell cycle and inhibition of protein
synthesis, de novo fatty acid synthesis, specifically the generation of mevalonate as well as other
products downstream of mevalonate in the cholesterol synthesis pathway. It is reported that AMPK
can regulate cell proliferation, cell growth and autophagy. It has been proposed to be a potential target
for cancer chemotherapy [19,20].
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Figure 5. Modulations of intracellular signaling pathways. Cells were treated with samples, or 
control for 72 h. Total protein was extracted for the analysis. A slide-based antibody array was used 
for simultaneous detection of 18 signaling molecules (a) when phosphorylated or cleaved using a 
PathScan Intracellular Signaling Array kit. Image (b) and quantitative data (c) for MCF-7 cells as 
well as image (d) and quantitative (e) data for MDA-MB-23 cells were obtained using a LiCor 
Odyssey imaging system. Data are presented as mean ± SD. * indicates a significant difference 
compared to the control (p < 0.05). # indicates a significant difference compared to treatment with 
samples by single (p < 0.05). 
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for 72 h. Total protein was extracted for the analysis. A slide-based antibody array was used for
simultaneous detection of 18 sig aling molecules (a) when phospho yla ed or cle ved using a PathScan
Intracellular Signaling Array kit. Image (b) and quantitative data (c) for MCF-7 cells as well as image
(d) and quantitative (e) data for MDA-MB-23 cells were obtained using a LiCor Odyssey imaging
system. Data are presented as mean ± SD. * indicates a significant difference compared to the control
(p < 0.05). # indicates a significant difference compared to treatment with samples by single (p < 0.05).
It reported that PI3K/Akt/mTOR signaling pathway activation is heavily implicated in cancer
pathogenesis [21]. Inhibited phosphorylation of Akt and mTOR in this study suggested that
inactivation of PI3K/Akt/mTOR pathway seems to be the main mechanism involved in anticancer
activity of bioactive anticarcinogens from soybean both in MCF-7 and MDA-MB-231 and cells.
To further confirm this hypothesis, the protein expression level of PI3K p85 was determined using
Western blot assay (Figure 6a–d). As shown, a reduction in the expression level of PI3K p85
was observed in these tested samples, which supported our hypothesis. In addition, change in
the phosphorylation of molecular proteins including stat3 (a key target in cancer cell growth),
Bad (a pro-apoptoic protein from Akt pathway), p53 (a pro-poptotic protein well known tumor
suppressor), p38 (a member of MAPK), PRAS40 (a protein which can inhibit Akt pathway) and
GSK-3β (a key regulator in tumor development) was observed in this study [22–26].
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ELISA Pico Chemiluminescent Substrate. Data are presented as mean ± SD. * indicates a significant 
difference compared to the control (p < 0.05). 
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Figure 6. The protein expression level of PI3K p85. Cells were treated with samples, or control for 72 h.
Total protein was extracted for the analysis using Western blot. The signal of target protein in MCF-7
cells (a,b) and MDA-MB-231 cells (c,d) was detected and quantified using SuperSignal ELISA Pico
Chemiluminescent Substrate. Data are presented as mean ± SD. * indicates a significant difference
compared to the control (p < 0.05).
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3. Materials and Methods
3.1. Chemicals
Genistein, daidzein, glycitein, genistin, daidzin, glycitin, equol, soyasaponin, β-sitosterol,
Bowman-birk trypsin inhibitor (BBI), lectin and insulin were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Lunasin was synthesized by the American Peptide Company (Sunnyvale, CA, USA).
2-(4-(2-hydroxyethyl)-1-piperazinyl)-ethanesulphonic acid (HEPES), Hank’s balancedsalt solution
(HBSS), fetal bovine serum (FBS), penicillin-streptomycin, phosphate-buffered saline (PBS) and
α-minimum essential medium (α-MEM) were purchased from Gibco BRL Life Technologies (Grand
Island, NY, USA). Methylene blue was purchased from BBL (Cockeysville, MD, USA). All reagents are
of analytical grade.
3.2. Preparation of Treatment Solution
Genistein, daidzein, glycitein, genistin, daidzin, glycitin, equol, soyasaponin and β-sitosterol
screened were prepared in 100% dimethyl sulfoxide (DMSO) at 10,000 µM. BBI, lunasin and lectin
were prepared in growth media at 5000 µM. These solutions were stored at −80 ◦C and used as stock
solution. Working solutions of all treatments were made through supplement with growth media until
the final concentrations of 0–200 µM.
3.3. Cell Culture
The MDA-MB-231 and MCF-7 human breast cancer cell lines were obtained from American
Tissue Type Culture Collection (ATCC, Bethesda, MD, USA). MDA-MB-231 cells were maintained
in α-MEM supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin and
1mM sodium pyruvate. MCF-7 cells were maintained in α-MEM supplemented with 10% FBS,
1% penicillin-streptomycin, 1 mM sodium pyruvate and 10 µg/mL insulin. All cells were grown in a
humidified atmosphere at 37 ◦C, with 5% CO2 in air.
3.4. Cell Proliferation Assay
The cell proliferation was determined using the methylene blue (98% HBSS, 0.67% glutaraldehyde,
0.6% methylene blue) assay as previously reported by Felice et al. [27]. MDA-MB-231 and
MCF-7 human breast cancer cells were respectively seeded into a 96-well plate at a density of
2.5 × 105 cells/well. After 16 h for MDA-MB-231 cells or 8 h for MCF-7 cells, the growth media
containing various concentrations (0–200 µM) of different treatment solutions were added to
MDA-MB-231 cells. After 72 h of incubation, cell proliferation was determined by measuring the
absorbance at 570 nm using a microplate reader (Bio-Rad, Hercules, MA, USA). An inhibition curve
of cell proliferation was achieved for each treatment solution and the effective median dose (EC50)
was determined.
3.5. Combination Study
The samples that showed stronger anti-proliferative effects (EC50 value < 200 µM) towards
human breast cancer cells were selected for the combination study. According to the EC50 value of
each treatment solution, two-way combination treatments were conducted. In detail, MCF-7 and
MDA-MB-231 cells were respectively seeded into a 96-well plate at a density of 2.5 × 105 cells/well.
For MCF-7 cells, the growth media was changed to media containing a series of concentrations
at different ratios of EC50 (0.125 × EC50, 0.25 × EC50, 0.50 × EC50, 0.75 × EC50, 1.00 × EC50,
and 1.25 × EC50) value of two selected samples, which include genistein plus daidzein, enistein plus
daidzein, genistein plus glycitein, genistein plus genistin, genistein plus daidzin, daidzein plus
glycitein, daidzeinplus genistin, daidzein plus daidzin, glycitein plus genistin, glycitein plus daidzin
or genistin plus daidzin, after 16 h incubation. For MDA-MB-231 cells, the growth media was changed
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to media containing a series of concentrations at different ratios of EC50 (0.125 × EC50, 0.25 × EC50,
0.50× EC50, 0.75× EC50, 1.00× EC50, and 1.25 × EC50) value of genistein plus glycitein, genistein plus
genistin, genistein plus β-sitosterol, glycitein plus genistin, glycitein plus β-sitosterol, β-sitosterol
plus genistin, after 8 h incubation. After 72 h of incubation, cell proliferation was determined and the
new EC50 value for each sample in combination study was calculated. Finally, a combination index
(CI) was calculated for each combination treatment at inhibition of 50% according to the method of
Yang et al. [10]. The CI50 value of a combination treatment less than 1 indicates a synergistic effect.
3.6. Cytotoxicity Assay
Cell cytotoxicity of bioactive anticarcinogens by single or two-way combination treatment, at the
concentration of their EC50 values, was assessed using the methylene blue assay [10,26] with some
modification. MDA-MB-231 and MCF-7 human breast cancer cells were respectively seeded into a
96-well plate at density of 5 × 105 cells/well and incubated for 24 h. For MCF-7 cells, cells were
then treated with genistein at 66.98 µM, daidzein at 130.14 µM, glycitein at 190.67 µM, genistin at
72.82 µM, daidzin at 179.21 µM and genistin plus daidzin at 26.21 µM plus 64.50 µM, or control for
24 h, respectively. For MDA-MB-231 cells, cells were treated with genistein at 93.75 µM, glycitein at
142.67 µM, genistin at 127.82 µM, β-sitosterol at 196.28 µM, genistein plus genistin at 33.61 µM plus
52.21 µM, genistein plus β-sitosterol at 24.08 µM plus 50.42 µM and β-sitosterol plus genistin at
37.71 µM plus 24.55 µM, or control for 24 h, respectively. The viability of cells was expressed as %
of control.
3.7. Wound Healing Assay
Samples which showed stronger anti-proliferative effects by single and combination treatments
having a synergistic effect were taken forwards to further investigate their capacity to inhibit breast
cancer cells invasion and migration.
Firstly, a wound-healing assay was conducted as reported by Kozlova et al. [28]. Briefly,
MCF-7 and MDA-MB-231 cells were respectively seeded into 6-well plate at 5 × 105/well and
grown in growth media until 90–100% confluency. After starvation in serum-free media overnight,
a cell-free area (wound) was constructed using 200 µL pipette tip in each well and washed gently with
ice-cold PBS for three times. Then serum-free media containing different samples were added to cells,
or control. The concentration of each sample used was the same with that described in cytotoxicity
assay. Healing of the wound was observed after 24 h by a light microscopy (CX-2, Olympus, Tokyo,
Japan) and analyzed using Image J software (NIH, Bethesda, MD, USA).
3.8. Transwell Chamber Assay
A transwell chamber assay was conducted using an extracellular matrix (ECM) invasion assay
kit (ECMatrix Cell Invasion Assay (Millipore, Billerica, MA, USA) according to the manufacturer’s
instruction. Briefly, MCF-7 and MDA-MB-231 cells were respectively suspended at 5 × 105 cells in
300 µL of serum-free media and plated on the top of an ECM-coated membrane insert. The assay was
terminated after 48 h with different treatment solutions or control. The concentration of each sample
used was the same with that described in the cytotoxicity assay. Then the cells on the upper side of the
insert were wiped off with a cotton swab and the cells on the lower side were stained with the solution
included in the invasion assay. The number of invasive cells was determined as described earlier for
the matrigel invasion assays in co-culture [29].
3.9. Intracellular Signaling Array
MCF-7 and MDA-MB-231 cells were respectively seeded into a 6-well plate at a density of
2.5 × 105 cells/well and treated with the different treatment solutions, or control, as described in the
anti-proliferative activity assay. The concentration of each sample used was the same with that described
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in the cytotoxicity assay. Whole cell lysates were collected using ice-cold lysis RIPA buffer (Fluorescent
Readout, Cell Signaling Technology, Danvers, MA, USA) supplemented with 1% PMSF and stored
at −20 ◦C until analysis. The PathScan Intracellular Signaling array kit (Fluorescent Readout,
Cell Signaling Technology, Danvers, MA, USA) was used according to the manufacturer’s instructions,
to simultaneously detect 18 phosphorylated or cleaved signaling molecules. The images were captured
and quantified using a LiCor Odyssey imaging system (Li-Cor Biosciences, Lincoln, NE, USA).
3.10. Western Blot Assay
The whole cell lysates collected in the last section were used to the Western blot assay was
performed according to previously described methods [30]. Total cellular protein was solubilized
in ice-cold lysis RIPA buffer. Anti-PI3K p85 HRP-conjugated secondary antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) were used. GAPDH protein was used as control. Target protein
were detected and quantified using SuperSignal ELISA Pico Chemiluminescent Substrate (Thermo
Fisher Scientific, Waltham, MA, USA).
3.11. Data Analysis
Data in this study were analyzed using one way ANOVA and Tukey’s test performed by SPSS
(Statistics for Social Science) version 17.0 (IBM, New York, NY, USA). All the assays were conducted in
triplicate (n = 3). Significant differences were reported at p < 0.05.
4. Conclusions
In conclusion, the present study provides insights into the anti-proliferative activity of
12 anticarcinogens from soybean against MCF-7 and MDA-MB-231 human breast cancer cell lines by
single or two-way combination treatment. Genistein, daidzein, gycitein, genistin and daidzin were
demonstrated to have stronger anti-proliferative activity against MCF-7cells with EC50 values less
than 200 uM. There is a synergistic effect of the combination treatment of genistin plus daidzinin
MCF-7 cells. Gensitein, glycitein, genistin and β-sitosterol showed stronger anti-proliferative activity
(EC50 values < 200 µM) against MDA-MB-231 cells and a synergistic effect was observed in the
combination of genistein plus genistin, genistein plus β-sitosterol and β-sitosterol plus genistin.
In addition, these bioactive anticarcinogens were also able to inhibit invasion and migration of breast
cancer cells and combination treatment enhanced the inhibitory effect. Regulation of PI3K/Akt/mTOR
pathway seems to be the main mechanisms involved in the anticancer activity. Our results may partly
contribute to the understanding of anticancer effect of dietary components in soybean. However,
further studies are needed in clinical trials.
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